{
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182810",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166182810",
    "name" : "Annotation of DPWG Guideline for flucloxacillin and HLA-B",
    "cancerGenome" : false,
    "guidelineGenes" : [ ],
    "history" : [ {
      "id" : 1450414938,
      "date" : "2019-05-23T00:00:00-07:00",
      "description" : "Annotation current with November 2018 DPWG Guideline release",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450820629,
      "date" : "2019-10-03T10:21:52.121-07:00",
      "description" : "No changes based on August 2019 guideline",
      "type" : "Note",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/15103288","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15103288,"resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","type":"Web Page","xrefs":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450815695,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"}]}, {"@id":"https://pharmgkb.org/literature/15102465","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15102465,"resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","type":"Web Page","xrefs":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450415575,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"}]} ],
    "recommendation" : true,
    "relatedAlleles" : [ {
      "@id" : "https://pharmgkb.org/haplotype/PA165987830",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165987830",
      "symbol" : "HLA-B*57:01",
      "name" : "*57:01",
      "version" : 2
    } ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA164781042",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA164781042",
      "name" : "flucloxacillin",
      "version" : 5
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA35056",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA35056",
      "symbol" : "HLA-B",
      "name" : "major histocompatibility complex, class I, B",
      "version" : 40
    } ],
    "source" : "Dutch Pharmacogenetics Working Group",
    "summaryMarkdown" : {
      "id" : 1450414935,
      "html" : "<p>Monitor for liver function and select an alternative drug instead of flucloxacillin if liver enzymes or bilirubin is elevated, for patients that are HLA-B*5701.</p>\n",
      "version" : 0
    },
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1450414936,
      "html" : "<h3 id=\"november-2018-guideline\">November 2018 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for flucloxacillin and HLA-B*5701.</p>\n<p><em>Wording in table taken from <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf\" target=\"_blank\">the Dutch guidelines</a></em></p>\n<table class=\"table\">\n<thead>\n<tr><th>ALLELE/GENOTYPE/PHENOTYPE</th><th>DRUG</th><th>DESCRIPTION</th><th>RECOMMENDATION</th></tr>\n</thead>\n<tbody>\n<tr><td>HLA-B*5701</td><td>flucloxacillin</td><td>HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals).</td><td>1. Regularly monitor the patientâ€™s liver function<br/>2. Choose an alternative if liver enzymes and/or bilirubin levels are elevated</td></tr>\n</tbody>\n</table>\n<p><a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0004652.PDF\" target=\"_blank\">Read for more information about this recommendation</a>, <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Read about gene information from DPWG</a></p>\n",
      "version" : 1
    },
    "userId" : "cfthorn",
    "version" : 2,
    "xrefs" : [ ]
  }
}